Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)
Fangyuan Cao, Sander de Weerd, Deng Chen, et al.
European Journal of Medicinal Chemistry (2020) Vol. 208, pp. 112800-112800
Open Access | Times Cited: 63

Showing 26-50 of 63 citing articles:

Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Structure-Based Discovery of Selective Histone Deacetylase 8 Degraders with Potent Anticancer Activity
Jinbo Huang, Jun Zhang, Wenchao Xu, et al.
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 2, pp. 1186-1209
Closed Access | Times Cited: 26
Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington’s Disease Pathology
Natsuko Macabuag, William Esmieu, Perla Breccia, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 18, pp. 12445-12459
Open Access | Times Cited: 23
Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer
Al‐Hassan M. Mustafa, Oliver H. Krämer
Pharmacological Reviews (2022) Vol. 75, Iss. 1, pp. 35-61
Closed Access | Times Cited: 22
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
Xuelian Liu, Anjin Wang, Yuying Shi, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1217-1217
Open Access | Times Cited: 13
HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation
Yufeng Xiao, Seth Hale, Nikee Awasthee, et al.
Cell chemical biology (2023) Vol. 30, Iss. 11, pp. 1421-1435.e12
Open Access | Times Cited: 13
Designing HDAC-PROTACs: Lessons Learned So Far
Fabian Fischer, Leandro A. Alves Avelar, Laoise Murray, et al.
Future Medicinal Chemistry (2021) Vol. 14, Iss. 3, pp. 143-166
Open Access | Times Cited: 28
The application of PROTAC in HDAC
Shaoting Chen, Yuxiang Zheng, Benji Liang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115746-115746
Closed Access | Times Cited: 11
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects
Jinxiao Ru, Yuxi Wang, Zijia Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115800-115800
Closed Access | Times Cited: 10
Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review
Mary Sravani Galla, Nitika Sharma, Priyanka Mishra, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 8, pp. 2585-2600
Closed Access | Times Cited: 3
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
PROTACs technology for targeting non-oncoproteins: Advances and perspectives
Chao Wang, Yujing Zhang, Dongming Xing, et al.
Bioorganic Chemistry (2021) Vol. 114, pp. 105109-105109
Closed Access | Times Cited: 24
PROTAC chemical probes for histone deacetylase enzymes
Urvashi Patel, Joshua P. Smalley, James T. Hodgkinson
RSC Chemical Biology (2023) Vol. 4, Iss. 9, pp. 623-634
Open Access | Times Cited: 9
Small-Molecule PROTACs for Cancer Immunotherapy
Zefan Liu, Yajun Zhang, Yucheng Xiang, et al.
Molecules (2022) Vol. 27, Iss. 17, pp. 5439-5439
Open Access | Times Cited: 14
Developments of PROTACs technology in immune-related diseases
Chao Wang, Yujing Zhang, Junwen Deng, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115127-115127
Open Access | Times Cited: 8
Histone Deacetylase 3‐Directed PROTACs Have Anti‐inflammatory Potential by Blocking Polarization of M0‐like into M1‐like Macrophages
Chunlong Zhao, Shipeng Chen, Deng Chen, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 42
Open Access | Times Cited: 8
Targeted protein modification as a paradigm shift in drug discovery
Roshanak Amirian, Mehdi Azadi Badrbani, Zhila Izadi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115765-115765
Closed Access | Times Cited: 8
From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology
Xuyang Zhao, Yifan Chen, Huang Su, et al.
Deleted Journal (2023) Vol. 1, Iss. 2
Open Access | Times Cited: 7
Therapeutic targeting of chromatin: status and opportunities
Marton I. Siklos, Stefan Kubicek
FEBS Journal (2021) Vol. 289, Iss. 5, pp. 1276-1301
Open Access | Times Cited: 16
Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection
Sana Zahid, Yasir Ali, Sajid Rashid
Journal of Biomolecular Structure and Dynamics (2023) Vol. 41, Iss. 23, pp. 14566-14581
Closed Access | Times Cited: 6
Bifunctional robots inducing targeted protein degradation
M. Elizabeth Sobhia, Harish Kumar, Sonia Kumari
European Journal of Medicinal Chemistry (2023) Vol. 255, pp. 115384-115384
Closed Access | Times Cited: 6
PROTACs targeting epigenetic proteins
Chao Zhang, Yuna He, Xiuyun Sun, et al.
Acta Materia Medica (2023) Vol. 2, Iss. 4
Open Access | Times Cited: 6
Advances in the Design and Development of PROTAC-mediated HDAC Degradation
Daniel A. Rodrigues, Andrew Roe, Darren M. Griffith, et al.
Current Topics in Medicinal Chemistry (2021) Vol. 22, Iss. 5, pp. 408-424
Open Access | Times Cited: 15
Cell-specific drug targeting in the lung
Soumeya Abed, Rebecca Turner, Nickolas Serniuck, et al.
Biochemical Pharmacology (2021) Vol. 190, pp. 114577-114577
Closed Access | Times Cited: 14
Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands
Yingxin Lu, Danwen Sun, Donghuai Xiao, et al.
Molecules (2021) Vol. 26, Iss. 23, pp. 7241-7241
Open Access | Times Cited: 14

Scroll to top